We are preparing the requested document. Please wait, this may take a while...!
|Antigen||B-Cell CLL/lymphoma 2 (BCL2) Antibodies|
|Epitope||AA 41-54 Alternatives|
|Conjugate||This BCL2 antibody is un-conjugated Alternatives|
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Flow Cytometry (FACS), Western Blotting (WB)
|7 references available|
|Supplier||Log in to see|
Product Details anti-BCL2 AntibodyTarget Details BCL2 Application Details Handling References for anti-BCL2 antibody (ABIN967322) Images
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
|Purification||The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.|
|Immunogen||Human Bcl-2 synthetic peptide aa. 41-54|
Target Details BCL2Product Details anti-BCL2 Antibody Application Details Handling References for anti-BCL2 antibody (ABIN967322) Images back to top
|Alternative Name||Bcl-2 (BCL2 Antibody Abstract)|
|Background||Bcl-2 is considered to be novel among proto-oncogenes because it blocks apoptosis (programmed cell death) in many cell types. Apoptosis is an active form of cellular suicide that typically requires new RNA and protein synthesis and is associated with distinct morphological changes including cell shrinkage, cytoplasm membrane blebbing, nuclear fragmentation and DNA degradation. Because Bcl-2 blocks apoptosis it may contribute to tumorigenisis by prolonging cell survival, rather than by accelerating the rate of cell proliferation. Human Bcl-2 protein migrates at a molecular weight of ~26 kDa by SDS-PAGE. Bcl-2/100 recognizes a 26 kDa band representing human Bcl-2. Additional minor bands at 27-31 kDa and 18-21 kDa may also be visualized. The 27-31 kDa upper band may represent a larger isoform, whereas the 18-21 kDa lower band may be an internal translation or proteolytic product, therefore, a synthetic peptide corresponding to amino acids 41-54 (GAAPAPGIFSSQPG) of human Bcl-2 was used as immunogen. This peptide sequence is not conserved between human and mouse. Bcl-2/100 does not cross-react with mouse Bcl-2. For detection of mouse Bcl-2 refer to clone 3F11 (ABIN967441), polyclonal rabbit anti-rat/mouse Bcl-2 antiserum, and polyclonal rabbit anti-mouse Bcl-2 antiserum.|
|Pathways||MAPK Signaling, PI3K-Akt Signaling, Apoptosis, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling|
Application DetailsProduct Details anti-BCL2 Antibody Target Details BCL2 Handling References for anti-BCL2 antibody (ABIN967322) Images back to top
|Application Notes||For paraffin-embedded sections, tissues should be fixed in either Bouin's fixative or formalin. Jurkat control lysate [50 µg (1 µg/µl)] is provided as a western blot positive control (store lysate at -20°C). Additional control lysate (ABIN968537) is sold separately. For flow cytometric analysis our directly conjugated formats are recommended.|
Related Products: ABIN968537
|Restrictions||For Research Use only|
HandlingProduct Details anti-BCL2 Antibody Target Details BCL2 Application Details References for anti-BCL2 antibody (ABIN967322) Images back to top
|Buffer||Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage Comment||Store undiluted at -20°C.|
References for anti-BCL2 antibody (ABIN967322)Product Details anti-BCL2 Antibody Target Details BCL2 Application Details Handling Images back to top
|Product cited in:||
Krajewski, Tanaka, Takayama, Schibler, Fenton, Reed: "Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes." in: Cancer research, Vol. 53, Issue 19, pp. 4701-14, 1993
Pezzella, Turley, Kuzu, Tungekar, Dunnill, Pierce, Harris, Gatter, Mason: "bcl-2 protein in non-small-cell lung carcinoma." in: The New England journal of medicine, Vol. 329, Issue 10, pp. 690-4, 1993
Tanaka, Saito, Reed: "Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival." in: The Journal of biological chemistry, Vol. 268, Issue 15, pp. 10920-6, 1993
Pezzella, Jones, Ralfkiaer, Ersbøll, Gatter, Mason: "Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma." in: British journal of cancer, Vol. 65, Issue 1, pp. 87-9, 1992
Reed, Meister, Tanaka, Cuddy, Yum, Geyer, Pleasure: "Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin." in: Cancer research, Vol. 51, Issue 24, pp. 6529-38, 1992
Williams: "Programmed cell death: apoptosis and oncogenesis." in: Cell, Vol. 65, Issue 7, pp. 1097-8, 1991
Pezzella, Tse, Cordell, Pulford, Gatter, Mason: "Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation." in: The American journal of pathology, Vol. 137, Issue 2, pp. 225-32, 1990
ImagesProduct Details anti-BCL2 Antibody Target Details BCL2 Application Details Handling References for anti-BCL2 antibody (ABIN967322) back to top